Aptamer shares jump as inks agreement with AstraZeneca

(Alliance News) - Aptamer Group PLC on Wednesday said it reached an agreement with AstraZeneca ...

Alliance News 3 July, 2024 | 8:57AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - Aptamer Group PLC on Wednesday said it reached an agreement with AstraZeneca PLC.

The York, England-based biotechnology firm said the agreement aims to explore Optimer vehicles for targeted delivery of small interfering RNA, known as siRNA.

Cambridge-based pharmaceutical company AstraZeneca will provide an siRNA to be trialled with Aptamer's Optimer-based delivery vehicle for fibrotic liver cells, Aptamer said.

Aptamer highlighted that the siRNA market was valued at over USD13 billion in 2023. "If successful Optimer-enabled delivery of siRNA could lead to the development of novel compounds that have significant advantages over current cell and tissue-targeting methods," the company explains.

Aptamer Chief Technical Officer Arron Tolley said: "Partnerships such as this will enable Aptamer Group to make rapid progress in this area, which is a key focus for Optimer technology. Targeted delivery to specific cell types remains a critical unmet need in many applications within the tissue targeting space and, as such, has been part of our strategic focus to support the development of binders with the potential for long-term, high value."

Aptamer shares jumped 18% to 0.74 pence per share, while AstraZeneca shares fell 0.4% to 12,036.00p each on Wednesday morning in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Aptamer Group PLC Ordinary Shares 0.69 GBX -0.86 -
AstraZeneca PLC 11,992.00 GBX -0.94

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures